Abstract:1 Intrathecal (i.t.) administration of prostaglandin E2 (PGE2) to conscious mice induced allodynia, a state of discomfort and pain evoked by innocuous tactile stimuli, and hyperalgesia as assessed by the hot plate test. We characterized prostaglandin E receptor subtypes (EP1–3) involved in these sensory disorders by use of 7 synthetic prostanoid analogues. 2 Sulprostone (EP1 < EP3) induced allodynia over a wide range of dosages from 50 pg to 5 μg kg−1. The maximal allodynic effect was observed at 5 min after i.t. injection, and the response gradually decreased over the experimental period of 50 min. This sulprostone‐induced allodynia showed a time course similar to that induced by PGE2. 3 17‐Phenyl‐ω‐trinor PGE2 (EP1 > EP3) and 16,16‐dimethyl PGE2 (EP1 = EP2 = EP3) were as potent as PGE2 in inducing allodynia, and more potent than sulprostone. Butaprost (EP2), 11‐deoxy PGE1 (EP2 = EP3), MB 28767 (EP3), and cicaprost (prostaglandin I2 (IP‐) receptor) induced allodynia, but with much lower scores. 13,14‐Dihydro‐15‐keto PGE2, a metabolite of PGE2, did not induce allodynia. 4 16,16‐Dimethyl PGE2 as well as PGE2 induced hyperalgesia over a wide range of dosages (16,16‐dimethyl PGE2: 5 pg–0.5 μg kg−1 PGE2: 50 pg–0.5 μg kg−1) with two apparent peaks at 0.5 ng kg−1 and 0.5 μg kg−1. Sulprostone (EP1 < EP3) and 17‐phenyl‐ω‐trinor PGE2 (EP1 > EP3) showed a bell‐shaped hyperalgesia at lower doses of 5 pg–5 ng kg−1 and 50 pg–50 ng kg−1, respectively. MB 28767 (EP3) showed a monophasic hyperalgesic action over a wide range of dosages at 50 pg–5 μg kg−1. Butaprost (EP2) induced hyperalgesia at doses higher than 50 ng kg−1. 5 These results demonstrate that PGE2 may exert allodynia through the EP1‐receptor and hyperalgesia through EP2‐ and EP3‐receptors in the mouse spinal cord.

Distinct Roles of Central and Peripheral Prostaglandin E2 and EP Subtypes in Blood Pressure Regulation

Prostaglandin E Receptors in Regulation of Blood Pressure

Single Hormone or Synthetic Agonist Induces Gs/Gi Coupling Selectivity of EP Receptors Via Distinct Binding Modes and Propagating Paths.

[Prostaglandin(pg) E2 in Regulation of Immunity and Inflammatory Diseases].

The Latest Progress in E-Prostanoid (EP) Receptor Subtypes EP2 and EP4

Ligand recognition, unconventional activation, and G protein coupling of the prostaglandin E<sub>2</sub> receptor EP2 subtype

The vasoconstrictor activities of prostaglandin D 2 via the thromboxane prostanoid receptor and E prostanoid receptor-3 outweigh its concurrent vasodepressor effect mainly through D prostanoid receptor-1 ex vivo and in vivo

Roles of the prostaglandin E 2 receptors EP subtypes in Alzheimer’s disease

Endothelial cell prostaglandin E2 receptor EP4 is essential for blood pressure homeostasis

The Role of GRIP1 and Ephrin B3 in Blood Pressure Control and Vascular Smooth Muscle Cell Contractility

Inactivation of the E-prostanoid 3 Receptor Attenuates the Angiotensin II Pressor Response Via Decreasing Arterial Contractility.

Physiology and pathophysiology of prostanoid receptors

The Double Roles of the Prostaglandin E2 EP2 Receptor in Intracerebral Hemorrhage

P2y(2) and G(Q)/G(11) Control Blood Pressure by Mediating Endothelial Mechanotransduction

The Emerging Therapeutic Role of Prostaglandin E2 Signaling in Pulmonary Hypertension

Prostanoids receptors signaling in different diseases/cancers progression.

Structural Insights into Selective and Dual Antagonism of EP2 and EP4 Prostaglandin Receptors

The P2Y6 receptor as a potential keystone in essential hypertension

Effects of prostaglandin I2 and a selective thromboxane synthetase inhibitor on the arteriolar constriction caused by norepinephrine

G protein-coupled receptor kinases in hypertension: physiology, pathogenesis, and therapeutic targets

Characterization of EP‐receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E2 to mice